Medicine & Life Sciences
Cost-Benefit Analysis
100%
Randomized Controlled Trials
71%
Suburethral Slings
42%
Costs and Cost Analysis
42%
Quality-Adjusted Life Years
40%
Stress Urinary Incontinence
36%
Pelvic Floor
34%
Systematic Reviews
34%
Urinary Incontinence
33%
Prolapse
25%
Lithotripsy
23%
Uterine Prolapse
23%
Artificial Urinary Sphincter
21%
Prostate
21%
Non-Randomized Controlled Trials
20%
Confidence Intervals
19%
Conservative Treatment
18%
Random Allocation
18%
Tamsulosin
18%
Muscles
18%
Hemorrhoidectomy
17%
Economics
17%
Urodynamics
16%
Transurethral Resection of Prostate
15%
Catheters
15%
Nifedipine
15%
Quality of Life
15%
Placebos
14%
Prostatectomy
14%
Root Caries
14%
Medication Therapy Management
14%
Pelvic Organ Prolapse
13%
Catheterization
13%
Therapeutics
13%
Biofeedback (Psychology)
12%
Cholecystitis
11%
Inlays
11%
Nitrofurazone
11%
Catheter-Related Infections
11%
Urinary Tract Infections
11%
OPAL protocol
10%
Gallstones
10%
Calcium Channel Blockers
10%
Cholecystectomy
10%
Ureter
9%
Ureteroscopy
9%
Uncertainty
9%
Odds Ratio
8%
Health Care Outcome Assessment
8%
nuclear matrix protein 22
8%
Social Sciences
costs
45%
surgery
36%
confidence
18%
life years
18%
management
15%
economics
12%
current management
11%
utility analysis
8%
quality of life
8%
evaluation
7%
Group
7%
adverse events
6%
drug therapy
6%
pragmatics
6%
heart disease
5%